Navigation Links
Integrium Introduces Its Integrium Clinical Excellence (ICE) Methodology to Assure Consistent Delivery of Sponsor Clinical Trials
Date:5/5/2008

TUSTIN, Calif., May 5 /PRNewswire/ -- Integrium, LLC(R), a cardiovascular and metabolic focused clinical research organization with a long history for delivering reliable results, has officially launched Integrium Clinical Excellence (ICE), a metric and performance-driven process designed to consistently deliver actionable results on time and on budget in all of its current and future clinical trial programs. ICE is a series of steps that provide a high level of transparency to Integrium sponsors to allow them to make confident, informed decisions for their clinical trials by minimizing risk factors and maximizing the timely implementation of contingencies to ensure success.

"After listening to our sponsors, we realized we can provide more value by further standardizing our processes and especially our feedback mechanisms," said Eileen McAuley, Chief Operating Officer at Integrium. "We continually strive to improve our methods, assess metrics and set higher standards for our project leaders to ensure success of our sponsors' development programs."

The standardized processes comprising ICE, feature four integrated steps that logically guide the sponsor through their clinical trial. Integrium has built new tools and metrics to track and measure the process via the ICE Project Scorecard. The four steps are:

o ICE Advance - To effectively support the Advance phase of any clinical

trial, Integrium brings years of clinical experience, the widely

accepted clinical knowledge of our medical staff and company founders,

and therapeutic foresight to evaluate each sponsor's specific study and

program plans before being awarded the trial. Integrium makes effective

use of its clinical site and Investigator databases, to provide a high

degree of predictability to site performances and commitments to

planned enrollment rates.

o ICE Alliance - A targeted Kick-off Meeting, attend
'/>"/>

SOURCE Integrium, LLC
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine news :

1. Anthem Blue Cross and Blue Shield in Connecticut Introduces Industrys First Electronic Tool to Help Members Search In-Network Doctors and Hospitals; Transparency Tool to Enable Searches Via Web-Enabled Cell Phones or Hand-Held Devices
2. Netsmart Technologies Introduces the Netsmart Connect(TM) Suite of Solutions for Behavioral and Public Healthcare
3. Anthem Blue Cross and Blue Shield Introduces Industrys Most Comprehensive Transparency Initiative to Wisconsin
4. Beautiful Teeth Not Just for the Dentists Office Anymore / SpaBrite Teeth Whitening System(TM) Introduces Innovative, New Teeth Whitening Experience To Spas
5. Internationally Renowned Plastic Surgery Coach Wendy Lewis Introduces Plastic Makes Perfect: The Complete Cosmetic Beauty Guide
6. Hero Nutritionals Introduces a New Adult Vitamin for the Taste Buds
7. Tubbs Jones Introduces Resolution Encouraging STD Prevention
8. Old Orchard Introduces First Multi-Serve Vitamin Water, Sweetened with Agave Nectar and Real Fruit Juice
9. CoolTouch Introduces CoolBlue Duet(TM) Laser Lipolysis Suction Handpiece
10. Dynatronics Introduces New DynaPro Spinal Health System and X5 Turbo
11. GHX Introduces NuVia(TM), an Artificial Intelligence-based Technology That Enables a New Approach to Content Management for Healthcare Providers
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Within3 Expands into Mobile Applications 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 1Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 2Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 3Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 4Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 5Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 6URI research couples method targets cancerous tumors 60165 1URI research couples method targets cancerous tumors 60165 2URI research couples method targets cancerous tumors 60165 3URI research couples method targets cancerous tumors 60165 4Scientists are first to observe the global motions of an enzyme copying DNA 10548 1Scientists are first to observe the global motions of an enzyme copying DNA 10548 2Scientists are first to observe the global motions of an enzyme copying DNA 10548 3Scientists are first to observe the global motions of an enzyme copying DNA 10548 4